NatWest Group’s Regeneron Pharmaceuticals REGN Stock Holding History

NatWest Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,906	Closed	-$887K	–	292
2015 Q3	$887K	Buy	+1,906	New	+$1.02M	0.02%	209
2015 Q2	–	Sell	-1,900	Closed	-$858K	–	417
2015 Q1	$858K	Buy	1,900 +321	+20%	+$136K	0.01%	236
2014 Q4	$648K	Buy	1,579 +872	+123%	+$343K	0.01%	274
2014 Q3	$255K	Buy	+707	New	+$237K	﹤0.01%	458
2014 Q1	–	Sell	-6,494	Closed	-$1.79M	–	673
2013 Q4	$1.79M	Buy	6,494 +972	+18%	+$280K	0.05%	293
2013 Q3	$1.73M	Sell	5,522 -11,815	-68%	-$3.11M	0.05%	285
2013 Q2	$3.9M	Buy	+17,337	New	+$4.04M	0.06%	223

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

NatWest Group's REGN Position: Q4 2015 in Review

NatWest Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2015, closing a stake of 1,906 shares — an estimated $887K sold.

NatWest Group first reported a position in REGN in Q2 2013 and held it in 7 quarters. The position peaked at $3.9M in Q2 2013. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2015.

NatWest Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 1,906 Regeneron Pharmaceuticals shares in Q4 2015, an estimated $887K.
NatWest Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 7 quarters.
NatWest Group's Regeneron Pharmaceuticals position peaked at $3.9M in Q2 2013.
577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.